Protocol No.: ARGX-113-2301

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
Principal Investigator
Nguyen, John
Phase
III
Age Group
Adult
Applicable Disease Site
Other
Participating Institutions
Eye Institute
West Virginia University
Contacts
Athena Echols
Clinical Trials Coordinator
Phone: +1 304-598-6977
Natalie London

View on ClinicalTrials.gov